Abstract: The present invention provides substantially amorphous fluvastatin sodium, anhydrous crystalline fluvastatin sodium and a novel polymorphic form of fluvastatin sodium, processes for preparation and pharmaceutical compositions thereof for antagonizing HMG-CoA. The novel polymorphic form is designated as Form R-16 of fluvastatin sodium.